Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05193344
Other study ID # SK-HF-99-002
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date January 15, 2022
Est. completion date December 31, 2023

Study information

Verified date May 2022
Source Sidekick Health
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study aim is to determine whether a 12-month digitally delivered behaviour change solution for patients with heart failure improves symptom frequency, mental health, quality of life, medication adherence, and self-care behaviour. The primary and secondary endpoints will be captured at 6- and 12-months follow-up visits to assess longer term effect on outcomes.


Description:

Heart Failure (HF) is one of the most common causes of morbidity and mortality in developed countries with a prevalence rate of 4.2% of the adult population and 11.8% among people ≥60 years of age. Worldwide HF affects about 26 million people and poses a significant burden on healthcare providers and patients. People with HF may have severe symptoms, and some may need a heart transplant or implantation of a ventricular assist device. Important modifiable HF risk factors are smoking, physical inactivity, overweight and obesity, and an unhealthy diet. Lifestyle changes by HF patients are known to reduce HF-related hospital (re)admission, morbidity and mortality. Guideline-directed treatment of HF includes among others pharmacotherapy, implantation of devices, regular exercise, and enrolment in a multidisciplinary care management program. Components of the multidisciplinary care management program are among others: patient education with an emphasis on adherence and self-care, patient involvement in symptom monitoring, and follow-up after discharge (for instance through remote monitoring). Adherence to the recommendations has proven difficult. A digitally delivered solution that provides remote symptom monitoring and lifestyle intervention support may support HF patients to halt or reverse disease progression and improve their quality of life. This study aims to digitally provide remote symptom monitoring and lifestyle intervention via a mobile platform (Sidekick Health) with the primary aim to determine the effectiveness of adding Sidekick Health's digital solution for HF patients to the standard care treatment by changes in the KCCQ-12 scores. The secondary aims are to determine the effect on other clinical outcomes (echocardiograms, biomarkers, metabolic syndrome symptoms, HF disease progression), other health-related outcomes (self-care, medication adherence, cardiorespiratory fitness, disease knowledge, smoking status, and anxiety, depression, and stress-levels), and cost-effectiveness.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 174
Est. completion date December 31, 2023
Est. primary completion date October 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adults with confirmed congestive HF registered at the outpatient heart failure clinic at the Landspitali University Hospital - Participants should be on one of these medications for heart failure treatment: angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blocker (ARB) inhibitors, or Angiotensin Receptor-Neprilysin Inhibitor - Participants with all stages of HF will be included (NYHA classes I-IV) - Started their medical HF treatment at least 1 month prior to study enrollment - Participants should be willing and able to comply with study procedures and attend the scheduled visits - Capacity to consent to informed consent Exclusion Criteria: - HF due to reversible causes (e.g., myocarditis) or severe aortic valve stenosis - Not owning a smartphone compatible with the Sidekick Health digital solution - Not knowing how to operate a smartphone - Moderate to severe dementia - Unable to understand written and verbal instructions in Icelandic. - estimated Glomerular Filtration Rate (eGFR) <15 ml/min - Planned dialysis in the next 6 months - Planned cardiac transplant surgery - Active drug/alcohol abuse - Other serious illness (e.g., cancer, endocarditis)

Study Design


Related Conditions & MeSH terms


Intervention

Device:
A digital care solution for patients with Heart Failure
A digital solution that provides remote symptom monitoring and support of lifestyle-changes by gamification, altruistic rewards, and engaging content with relevant tasks or missions to be completed.
Other:
Standard of Care for patients with Heart Failure
The best medical therapy including start or optimization of secondary preventive pharmacotherapy, and advise on modifiable risk factors. The participants in the control arm will also receive an information leaflet about relevant lifestyle modifications for HF.

Locations

Country Name City State
Iceland Landspitali University Hospital Reykjavík

Sponsors (2)

Lead Sponsor Collaborator
Sidekick Health Landspitali University Hospital

Country where clinical trial is conducted

Iceland, 

Outcome

Type Measure Description Time frame Safety issue
Other Exploratory Objective: Outcome prediction and validation between in-app and clinical metrics Associations between physical assessments and vital signs, clinical questionnaire outcomes, in-app PROs and stress levels, energy levels and quality of sleep. 12 months
Other Exploratory Objective: Predictive value of the disease specific in-app remote symptom monitoring for HF disease progression. In-app disease specific remote symptom monitoring score change compared to changes over time in the other outcome measures. 12 months
Other Safety objective: Monitor the safety and any potential adverse effects of the digital solution on patients and outcomes. Therapy discontinuation or adverse event reportings due to participation in the intervention. 12 months
Primary Effectiveness for patients with HF Change in HF-induced symptom frequency, physical and social limitations, and quality of life impairment, from baseline to 12 months. This primary outcome will be as measured with the 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12).
The KCCQ-12 score ranges from a minimum of 0 to a maximum of 100, where 100 is the best possible score indicating no symptoms, no limitations, and an excellent quality of life.
12 months
Secondary Resource utilization (cost-effectiveness) Resource utilization (e.g. number of visits over time to the ER, hospital outpatient unit (and hospital visits in general) due to worsening of heart failure at 6 and 12 months. 12 months
Secondary Echocardiogram - ejection fraction Change in ejection fraction (percent value) for patients with Heart Failure with reduced Ejection Fraction (HFrEF) at 6 months. 6 months
Secondary Echocardiogram - change in left atrium size Change in left atrium size for patients with Heart failure with preserved Ejection Fraction (HFpEF) at 6 months. 6 months
Secondary HF-specific laboratory values Change in N-terminal pro-Brain Natriuretic Peptide (NT-proBNP) at 6 months. 6 months
Secondary Symptoms of the metabolic syndrome (MetSyn). Participant number of MetSyn features (0-5) change from baseline to 6 months, compared between groups. 6 months
Secondary Cardiorespiratory fitness Change in outcomes on the 6 minute walking test (6MWT) from baseline to 6 months 6 months
Secondary HF disease progression classified with NYHA Compare changes in New York Heart Association (NYHA) classification from baseline to 6 and 12 months. The NYHA classifies heart disease in four classes, I to IV, based on symptoms. Class IV is the most severe heart disease. 12 months
Secondary HF disease progression classified with Killip Compare changes in Killip classification from baseline to 6 and 12 months. Killip classifies acute myocard infarction patients into four classes: class I to IV. Class IV is the most severe case with the highest mortality risk. 12 months
Secondary Medication adherence Compare self-reported medication adherence from baseline to 6 and 12 months, using the eight-item Morisky Medication Adherence Scale (MMAS-8) and electronic health record (EHR) medication refill information. 12 months
Secondary Patient self-care Compare between groups score from the nine-item European Heart Failure Self-care Behaviour (EHFScB-9) scale from baseline to 3 and 6 months. The score on the EHFScB-9 scale can range from a minimum of 9 to a maximum of 45, with higher scores indicating worse self-care. 6 months
Secondary Patient disease knowledge Compare between groups score from a 6-item HF disease-specific knowledge questionnaire, from baseline to 3 and 6 months. The score on the questionnaire can range from a minimum of 6 to a maximum of 30, with higher scores indicating less HF disease specific knowledge. 6 months
Secondary Smoking status Changes in self-reported smoking status, from baseline to 6 months. 6 months
Secondary Depression, anxiety, and stress-levels Changes in outcomes on the 21-item Depression, Anxiety and Stress Scale (DASS-21) from baseline to 3, 6, and 12 months. The DASS-21 consists of three 7-item scales on which the scores range from a minimum of 0 to a maximum of 21, with higher scores indicating higher levels of anxiety, depression, or stress. 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT05654272 - Development of CIRC Technologies
Active, not recruiting NCT05896904 - Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction N/A
Completed NCT05077293 - Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
Recruiting NCT05631275 - The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
Enrolling by invitation NCT05564572 - Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology N/A
Enrolling by invitation NCT05009706 - Self-care in Older Frail Persons With Heart Failure Intervention N/A
Recruiting NCT04177199 - What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
Terminated NCT03615469 - Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY) N/A
Recruiting NCT06340048 - Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure Phase 1/Phase 2
Recruiting NCT05679713 - Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
Completed NCT04254328 - The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure N/A
Completed NCT03549169 - Decision Making for the Management the Symptoms in Adults of Heart Failure N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05538611 - Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
Recruiting NCT04262830 - Cancer Therapy Effects on the Heart
Completed NCT06026683 - Conduction System Stimulation to Avoid Left Ventricle Dysfunction N/A
Withdrawn NCT03091998 - Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support Phase 1
Recruiting NCT05564689 - Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy